Synchronous BRAF^V600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity

References

• HodisEWatsonIRKryukovGVA landscape of driver mutations in melanomaCell2012150225126322817889
   PubMed Web of Science ®Google Scholar
• SmalleyKSUnderstanding melanoma signaling networks as the basis for molecular targeted therapyJ Invest Dermatol20101301283719571822
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJDemidovLPhase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanomaAnnual Meeting Program, American Society of Clinical OncologyJune 1–5, 2012Chicago, IL, USA Abstract LBA 8500
   Google Scholar
• FlahertyKTRobertCHerseyPMETRIC Study GroupImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• KirkwoodJMBastholtLRobertCPhase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaClin Cancer Res201218255556722048237
   PubMed Web of Science ®Google Scholar
• LoRussoPMKrishnamurthiSSRinehartJJPhase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancersClin Cancer Res20101661924193720215549
   PubMed Web of Science ®Google Scholar
• FalchookGSLewisKDInfanteJRActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialLancet Oncol201213878278922805292
   PubMed Web of Science ®Google Scholar
• SullivanRJFlahertyKTResistance to BRAF-targeted therapy in melanomaEur J Cancer20134961297130423290787
   PubMed Web of Science ®Google Scholar
• GregerJGEastmanSDZhangVCombinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsMol Cancer Ther201211490992022389471
   PubMed Web of Science ®Google Scholar
• CorcoranRBDias-SantagataDBergethonKIafrateAJSettlemanJEngelmanJABRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutationSci Signal20103149ra8421098728
   PubMed Web of Science ®Google Scholar
• LittleASBalmannoKSaleMJAmplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cellsSci Signal20114166ra1721447798
   PubMed Web of Science ®Google Scholar
• PoulikakosPISolitDBResistance to MEK inhibitors: should we co-target upstream?Sci Signal20114166e16
   Web of Science ®Google Scholar
• SuFVirosAMilagreCRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsN Engl J Med2012366320721522256804
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• GonzalezRRibasADaudAPhase IB Study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7)Presented at: European Society for Medical Oncology CongressSeptember 28–October 2, 2012 Abstract LBA28_PR. Available from: http://abstracts.webges.com/esmo2012/myitinerary
   Google Scholar
• HooijkaasAIGadiotJvan der ValkMMooiWJBlankCUTargeting BRAF(V600E) in an inducible murine model of melanomaAm J Pathol2012181378579422796458
   PubMed Web of Science ®Google Scholar
• HooijkaasAGadiotJMorrowMStewartRSchumacherTBlankCSelective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanomaOncoImmunology201216715
   Google Scholar
• DankortDCurleyDPCartlidgeRABraf(V600E) cooperates with Pten loss to induce metastatic melanomaNat Genet200941554455219282848
   PubMed Web of Science ®Google Scholar
• GilmartinAGBleamMRGroyAGSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibitionClin Cancer Res2011175989100021245089
   PubMed Web of Science ®Google Scholar
• TsaiJLeeJTWangWDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProc Natl Acad Sci U S A200810583041304618287029
   PubMed Web of Science ®Google Scholar
• BalagulaYBarth HustonKBusamKJLacoutureMEChapmanPBMyskowskiPLDermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)Invest New Drugs20112951114112120978926
   PubMed Web of Science ®Google Scholar
• DumesicPASchollFABarraganDIKhavariPAErk1/2 MAP kinases are required for epidermal G2/M progressionJ Cell Biol2009185340942219414607
   PubMed Web of Science ®Google Scholar
• CichowskiKJännePADrug discovery: inhibitors that activateNature2010464728735835920237552
   PubMed Web of Science ®Google Scholar
• BlankCUHooijkaasAIHaanenJBSchumacherTNCombination of targeted therapy and immunotherapy in melanomaCancer Immunol Immunother201160101359137121847631
   PubMed Web of Science ®Google Scholar
• ParaisoKHFedorenkoIVCantiniLPRecovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyBr J Cancer2010102121724173020531415
   PubMed Web of Science ®Google Scholar
• FridayBBYuCDyGKBRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteinsCancer Res200868156145615318676837
   PubMed Web of Science ®Google Scholar
• ByronSALochDCWellensCLSensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusMol Cancer2012117523039341
   PubMed Web of Science ®Google Scholar
• ParaisoKHXiangYRebeccaVWPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionCancer Res20117172750276021317224
   PubMed Web of Science ®Google Scholar